Loading
Ovarian Function and Disorders / Pituitary Gland Disorders and Treatments · Journal article
World Journal of Pharmacy and Pharmaceutical Sciences · September 3, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a narrative systematic review that identifies lean PCOS (20–30% of PCOS cases) as a distinct neuroendocrine phenotype characterized by accelerated GnRH pulsatility and diagnostic delays of 5–15 years, driven by clinical bias toward obese phenotypes. The review proposes that standard therapies mask rather than address the underlying neuroendocrine drivers and calls for phenotype-specific interventions, but reports no comparative efficacy data, trial outcomes, or quantitative evidence to support specific therapeutic recommendations.
Systematic review. Patients with polycystic ovary syndrome, particularly those with normal or low BMI (lean phenotype)..
Lean PCOS phenotype affects 20–30% of PCOS patients but is underrecognized due to clinical bias. Diagnostic delays in lean PCOS span 5 to 15 years, driven by mimicry of pubertal maturation. Lean PCOS pathophysiology is characterized by accelerated GnRH pulse frequency and pulsatile LH increase, independent of systemic insulin resistance.
Efficacy and safety of proposed phenotype-specific interventions are not compared or quantified.
Clinicians should recognize that lean PCOS represents a distinct neuroendocrine phenotype often missed due to diagnostic bias and that standard hormonally active contraceptives may mask rather than address the underlying reproductive neuroendocrine dysfunction. However, this review provides no comparative data on therapeutic efficacy to guide treatment selection.
This is a systematic review that synthesizes existing evidence on lean PCOS pathophysiology and diagnostic delays, but reports no primary data, effect sizes, or comparative trial results to support actionable clinical recommendations.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that lean PCOS represents a distinct neuroendocrine phenotype often missed due to diagnostic bias and that standard hormonally active contraceptives may mask rather than address the underlying reproductive neuroendocrine dysfunction. However, this review provides no comparative data on therapeutic efficacy to guide treatment selection.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Polycystic Ovary Syndrome (PCOS)—recently redefined in global consensus statements as Polyendocrine Metabolic Ovarian Syndrome (PMOS)—is typically characterized in clinical literature by its strong association with obesity and insulin resistance. However, a significant subset of patients (20–30%) present with a normal or low body mass index (BMI), defining the "lean PCOS" phenotype. This cohort experiences extensive diagnostic delays, often spanning 5 to 15 years, due to clinical biases that overlook non-obese phenotypes and the diagnostic mimicry of pubertal maturation. Pathophysiologically, lean PCOS is distinctly driven by reproductive neuroendocrine aberrations, primarily a profound acceleration in gonadotropin-releasing hormone (GnRH) pulse frequency and a subsequent increase in pulsatile luteinizing hormone (LH) secretion, operating independently of weight-induced metabolic syndrome. Although insulin resistance exists in lean phenotypes, it remains predominantly tissue-specific or visceral rather than systemic. Standard therapies, such as non-targeted combined oral contraceptive pills (COCPs), frequently mask symptoms while exacerbating subclinical metabolic profiles or inducing hypothalamic-pituitary-ovarian axis suppression. This systematic review synthesizes recent clinical trials and mechanistic insights to delineate the neuroendocrine and metabolic pathways of lean PCOS, quantifies the drivers of clinical diagnostic delays, and provides an evidence-based framework for targeted, phenotype-specific therapeutic interventions.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.